NUR 5461 MODULE 4 EXAM SCRIPT 2026
ADVANCED NURSING PRACTICE AND
EVIDENCE BASED CARE COMPLETE
SOLUTION VIEW
◉ MS management
symptoms- fatigue
Answer: amantadine
modafinil
◉ MS management
urinary symptoms
Answer: flomax
urodynamics, intermittent self-catheterization
◉ MS management
muscle spasticity symptoms
Answer: exercise/PT
muscle relaxants/ benzodiazepines
◉ MS management
, depression
Answer: 50% lifetime
SSRIs
◉ MS relapses
Answer: not all need to be treated
assess gait and vision
Distinguish between new attack and pseudo attack
shorten the duration and severity of the attack by - corticosteroids
(60-80 mg qd one week then slow taper)
Gold standard: methylprednisolone: 1gm qd IV 3-5 days
not as much evidence for plasmapheresis, immunosuppression
pseudo attack- may have signs and symptoms, but from other
source, like infection or stress
◉ Long term Therapies for MS
Answer: no approved therapies for PPMS
2 recombinant interferon beta
RRMS- IFN-beta-1a (avonex)
Glatiramer acetate (Copaxone) myelin-like polypeptide
ADVANCED NURSING PRACTICE AND
EVIDENCE BASED CARE COMPLETE
SOLUTION VIEW
◉ MS management
symptoms- fatigue
Answer: amantadine
modafinil
◉ MS management
urinary symptoms
Answer: flomax
urodynamics, intermittent self-catheterization
◉ MS management
muscle spasticity symptoms
Answer: exercise/PT
muscle relaxants/ benzodiazepines
◉ MS management
, depression
Answer: 50% lifetime
SSRIs
◉ MS relapses
Answer: not all need to be treated
assess gait and vision
Distinguish between new attack and pseudo attack
shorten the duration and severity of the attack by - corticosteroids
(60-80 mg qd one week then slow taper)
Gold standard: methylprednisolone: 1gm qd IV 3-5 days
not as much evidence for plasmapheresis, immunosuppression
pseudo attack- may have signs and symptoms, but from other
source, like infection or stress
◉ Long term Therapies for MS
Answer: no approved therapies for PPMS
2 recombinant interferon beta
RRMS- IFN-beta-1a (avonex)
Glatiramer acetate (Copaxone) myelin-like polypeptide
